Beta‑Blocker Use and Endoscopic Surveillance in Cirrhotic Patients Without Varices

Efficacy of Non‑Selective Beta‑Blockers

A randomized trial published in Hepatology (2007) demonstrated that non‑selective beta‑blockers do not prevent the development of esophageal varices in patients with compensated cirrhosis who have no varices at baseline. 1

For patients with compensated cirrhosis and no varices on initial screening endoscopy, surveillance esophagogastroduodenoscopy (EGD) should be performed every 2–3 years (moderate‑quality evidence). 1
If a patient progresses to decompensated cirrhosis, the surveillance interval should be yearly EGDs (moderate‑quality evidence). 1

Non‑invasive markers such as platelet count, spleen size, and transient elastography have unsatisfactory predictive accuracy for detecting varices and therefore cannot replace endoscopic screening in this population (moderate‑quality evidence). 1

Economic models that propose universal beta‑blocker therapy without prior endoscopic screening are not supported, because beta‑blockers fail to prevent variceal development and are associated with a notable adverse‑effect profile (moderate‑quality evidence). 1

Patients who are already taking non‑selective beta‑blockers for other indications (e.g., arterial hypertension) may avoid screening endoscopy, as they already have prophylactic therapy should varices develop (moderate‑quality evidence). 1

The American Association for the Study of Liver Diseases (AASLD) recommends that beta-blockers should not be used in patients with compensated cirrhosis and no varices, as they do not prevent variceal development and cause significant adverse effects 2
In patients with small varices, nonselective beta-blockers should be reserved only for those with high-risk features, such as Child B/C cirrhosis or red wale marks on varices, as recommended by the AASLD 2

The AASLD recommends performing surveillance endoscopy every 2-3 years in compensated cirrhosis patients without varices to monitor for variceal development 2, 3
In patients with small varices without high-risk features, surveillance endoscopy should be performed every 1-2 years, as recommended by the AASLD 2, 3

The AASLD recommends initiating nonselective beta-blockers immediately in patients with small varices accompanied by high-risk features, such as Child-Pugh class B or C cirrhosis, or red wale marks on the varices 2, 4, 5
Propranolol should be started at 40 mg once daily and titrated to maximal tolerated dose, as recommended by the AASLD 2, 4, 5
Nadolol should be started at 40 mg once daily and titrated to maximal tolerated dose, as recommended by the AASLD 2, 5

Beta-blockers should not be used in patients with asthma or severe COPD, heart block or significant bradycardia, hypotension, or decompensated heart failure, as recommended by the AASLD 4, 5, 6